RTOG: Hormone Therapy Increases Survival When Combined With Radiation Therapy
Zaltrap Shows Improvement in Survival In Stage IV Metastatic Colorectal Cancer
Trial: Decitabine Improves Survival in Myeloid Leukemia
Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival
VEGF Levels Can Predict Tumor’s Resistance to Avastin
More Patients Get Screened, Colorectal Death Rates Drop
Revlimid Shows 91 Percent Response in Non-Hodgkin’s
Revlimid Also Demonstrates Response in Mantle Cell
FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response
Overall Cancer Mortality Rates Higher For Men Than Women
New Model For Risk Assessment Includes Alcohol, Exercise, Weight
Researchers Identify Five Genes Associated With Melanoma Risk
Stereotactic Body Radiotherapy Could Improve Overall Survival
CMS Issues Coverage Decision For Provenge in Prostate Cancer
Clinical Trials Approved By NCI CTEP Last Month
Approval Granted For New Formulation of Lupron Depot
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
